# Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer

Source: https://onco.cc/trials/nct07469956/  
OnCo record `nct07469956` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of surufatinib, toripalimab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Sun Yat-sen University, not yet recruiting.

## Summary

Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT07469956 by Sun Yat-sen University, with a registry enrolment figure of 30 participants, started 2026-03-31 and due to reach its primary completion in 2028-01-31. Interventions recorded: Surufatinib; Toripalimab; mFOLFIRINOX. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: 12-month Event Free Survival Rate. Pancreatic eligibility wording from the registry: "Patients with high-risk resectable or borderline resectable pancreatic cancer confirmed by pathological tissue or cytology:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07469956
- Phase: 2
- Setting: Neoadjuvant Therapy With Surufatinib Combined With mFOLFIRINOX and Toripalimab for High-risk or Borderline Resectable Pancreatic Cancer: A Phase II, Single-arm, Single-center Study
- Sponsor: Sun Yat-sen University
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07469956: https://clinicaltrials.gov/study/NCT07469956

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRINOX / mFOLFIRINOX](https://onco.cc/drugs/folfirinox/), [Surufatinib](https://onco.cc/drugs/surufatinib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07469956.json